Quantitative Alterations in Short-Chain Fatty Acids in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.

IF 4.8 2区生物学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biomolecules Pub Date : 2025-07-15 DOI:10.3390/biom15071017

Laura Chulenbayeva, Zharkyn Jarmukhanov, Karlygash Kaliyekova, Samat Kozhakhmetov, Almagul Kushugulova

{"title":"Quantitative Alterations in Short-Chain Fatty Acids in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.","authors":"Laura Chulenbayeva, Zharkyn Jarmukhanov, Karlygash Kaliyekova, Samat Kozhakhmetov, Almagul Kushugulova","doi":"10.3390/biom15071017","DOIUrl":null,"url":null,"abstract":"Background: Reduced short-chain fatty acids (SCFAs) in inflammatory bowel disease (IBD) impair the gut barrier and immune function, promoting inflammation and highlighting microbiome-targeted therapies' therapeutic potential. The purpose of this meta-analysis was to study the changes in SCFAs in IBD and their potential role in the occurrence and development of IBD.Methods: The analysis employed a random-effects model to assess the standardized mean difference (SMD) with a 95% confidence interval. A literature search was conducted in databases from 2014 to 20 July 2024 to identify studies investigating SCFAs in IBD.Results: Subgroup analyses revealed a significant reduction in fecal SCFA levels-specifically butyrate, acetate, and propionate-in all IBD subgroups compared to healthy controls. Active IBD showed a greater decrease in butyrate (p = 0.004), and UC showed a notable reduction in propionate (p = 0.03). When comparing UC and CD, differences were observed mainly in propionate (SMD = -0.76, p = 0.00001). Dietary interventions in IBD patients led to increased SCFA levels, with butyrate showing the most improvement (SMD = 1.03), suggesting the potential therapeutic value of dietary modulation.Conclusions: In conclusion, this meta-analysis demonstrates a significant reduction in fecal SCFA levels in patients with IBD, particularly during active phases of the disease and most markedly in CD.","PeriodicalId":8943,"journal":{"name":"Biomolecules","volume":"15 7","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12292850/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomolecules","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3390/biom15071017","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Reduced short-chain fatty acids (SCFAs) in inflammatory bowel disease (IBD) impair the gut barrier and immune function, promoting inflammation and highlighting microbiome-targeted therapies' therapeutic potential. The purpose of this meta-analysis was to study the changes in SCFAs in IBD and their potential role in the occurrence and development of IBD.

Methods: The analysis employed a random-effects model to assess the standardized mean difference (SMD) with a 95% confidence interval. A literature search was conducted in databases from 2014 to 20 July 2024 to identify studies investigating SCFAs in IBD.

Results: Subgroup analyses revealed a significant reduction in fecal SCFA levels-specifically butyrate, acetate, and propionate-in all IBD subgroups compared to healthy controls. Active IBD showed a greater decrease in butyrate (p = 0.004), and UC showed a notable reduction in propionate (p = 0.03). When comparing UC and CD, differences were observed mainly in propionate (SMD = -0.76, p = 0.00001). Dietary interventions in IBD patients led to increased SCFA levels, with butyrate showing the most improvement (SMD = 1.03), suggesting the potential therapeutic value of dietary modulation.

Conclusions: In conclusion, this meta-analysis demonstrates a significant reduction in fecal SCFA levels in patients with IBD, particularly during active phases of the disease and most markedly in CD.

查看原文本刊更多论文

短链脂肪酸在炎症性肠病中的定量改变：一项系统综述和荟萃分析。

背景：炎症性肠病（IBD）中减少的短链脂肪酸（SCFAs）损害肠道屏障和免疫功能，促进炎症，并突出了微生物组靶向治疗的治疗潜力。本荟萃分析的目的是研究SCFAs在IBD中的变化及其在IBD发生和发展中的潜在作用。方法：采用随机效应模型评估标准化平均差（SMD），置信区间为95%。在2014年至2024年7月20日的数据库中进行文献检索，以确定研究IBD中scfa的研究。结果：亚组分析显示，与健康对照组相比，所有IBD亚组的粪便SCFA水平显著降低，特别是丁酸盐、醋酸盐和丙酸盐。活动性IBD显示丁酸盐明显降低（p = 0.004）， UC显示丙酸盐明显降低（p = 0.03）。UC与CD比较，差异主要在丙酸盐（SMD = -0.76, p = 0.00001）。IBD患者的饮食干预导致SCFA水平升高，其中丁酸盐的改善效果最大（SMD = 1.03），提示饮食调节具有潜在的治疗价值。结论：总而言之，这项荟萃分析表明，IBD患者的粪便SCFA水平显著降低，特别是在疾病的活跃期，在CD中最明显。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomolecules Biochemistry, Genetics and Molecular Biology-Molecular Biology

CiteScore

9.40

自引率

3.60%

发文量

1640

审稿时长

18.28 days

期刊介绍： Biomolecules (ISSN 2218-273X) is an international, peer-reviewed open access journal focusing on biogenic substances and their biological functions, structures, interactions with other molecules, and their microenvironment as well as biological systems. Biomolecules publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.